Treatment of Progressive Multiple Sclerosis-related Cognitive Impairment, Fatigue, and Depression Using Repetitive Transcranial Magnetic Stimulation

Science Technology and Innovation Funding Authority0 个研究点目标入组 60 人开始时间: 2024年1月14日最近更新: 2024年4月8日

适应症

试验速览

暂无简介。

•Definite MS patients according to 2017 revisions of the McDonald criteria.
•-Progressive types of MS: Patient must fulfill diagnostic criteria of either: Secondary progressive MS (SPMS) or Primary progressive MS (PPMS)
•-Free of clinical relapses for at least 3 months prior to inclusion.
•-Free of steroid treatment for at least 6 weeks prior to inclusion.
•-No change in their medications, whether disease modifying treatment or symptomatic therapy for at least 3 months if applicable.
•-EDSS score below 6 points and stable over the past 3 months.
•-A score of <34 on Symbol Digit Modalities Test, a score of = 12 on the Beck Depression Inventory (Beck et al., 1961), a score of = 38 on the Modified Fatigue Impact Scale.
•-Level of education: at least can read and write.
•-Written informed consent from the participants

•-Conditions that could affect the participants’ level of cognition, fatigue, or depression, including; pregnancy, history of substance use disorder, history of significant neurological disorder other than MS, psychiatric, endocrinological, hepatic, renal, collagen, or other systemic comorbidities that could affect these symptoms.
•-Contraindication to TMS: history of seizures, skull bone defects, metal fragments in the head, implanted metallic devices such as cardiac pacemakers, cochlear implants, medical pumps…, etc.
•-Illiterate patients.

发起方

Science Technology and Innovation Funding Authority